Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: antibody-based cancer therapeutics - Affimed Therapeutics

Alternative Names: AFM 12; AFM 18; AFM 20; AFM 21; AFM 22; AFM 24+; AFM24_I; AFM24_T; anti CD19 x anti CD16; anti CD33 X anti CD3; anti-EGFRvIII/CD16A Tand AB; anti-EGFRvIII/CD3 TandAb; anti-EpCAM TandAb; Antibody-based non-Hodgkin's lymphoma therapeutics - Affimed; MHC-peptide complex antibody - Affimed; Trispecific Abs

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affimed Therapeutics
  • Developer Affimed Therapeutics; Amphivena Therapeutics
  • Class Bispecific antibodies; Immunotherapies; Monoclonal antibodies; Trispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; B-cell maturation antigen modulators; CD19 antigen modulators; CD200 antigen modulators; CD3 antigen modulators; CD33 antigen modulators; Epidermal growth factor receptor antagonists; Epithelial cell adhesion molecule inhibitors; FCGR3A protein modulators; Immunomodulators; Major histocompatibility complex inhibitors; Matrix metalloproteinase 1 inhibitors; Natural killer cell stimulants; Phagocyte stimulants; T lymphocyte stimulants; T-lymphocyte differentiation antigen agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 28 Aug 2024 Discontinued - Preclinical for Acute myeloid leukaemia in Germany (Parenteral) (Affimed Therapeutics pipeline, August 2024)
  • 28 Aug 2024 Discontinued - Preclinical for Cancer in Germany (Parenteral) (Affimed Therapeutics pipeline, August 2024)
  • 28 Aug 2024 Discontinued - Preclinical for Colorectal cancer in Germany (Parenteral) (Affimed Therapeutics pipeline, August 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top